business / news / / NDTV Profit
Gujarat Themis Biosyn Ltd. will acquire a portfolio of anti-tuberculosis (TB) and anti-infective brands from Sanofi.
Gujarat Themis Biosyn is acquiring 13 branded generic products from Sanofi for Euro 158 million.
KEY POINTS
- The acquired portfolio covers over 55 countries in Europe, Middle East, and Africa.
- No manufacturing facilities or employees will transfer, keeping the deal asset-light and capital-efficient.
- The transaction is expected to close by December 2026 and be EPS accretive for GTBL.
COMPANIES
Summarized by Newsio from NDTV Profit. How we summarize →